Evidence map›Paper›PMID 33015549›Full record

ArticleSN comprehensive clinical medicine2020

Are We Jumping the Gun with Itolizumab in India? A Situational Analysis from the Pre-COVID Era.

Pugazhenthan Thangaraju, Nanditha Venkatesan, Eswaran Thangaraju, Sajitha Venkatesan

Abstract read
In one paragraph

Article in SN comprehensive clinical medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Severe bronchospasm following itolizumab infusion in a COVID-19 patient.Journal of anaesthesiology, clinical pharmacology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Pugazhenthan ThangarajuDepartment of Pharmacology, All India Institute of Medical Sciences (AIIMS), Raipur, Chhattisgarh India.ORCID 0000-0002-4090-2004
Nanditha VenkatesanAll India Institute of Medical Sciences (AIIMS), Raipur, Chhattisgarh India.
Eswaran ThangarajuAKT Memorial College of engineering and technology, Kallakurichi, Tamil Nadu India.
Sajitha VenkatesanDepartment of Microbiology, All India Institute of Medical Sciences (AIIMS), Raipur, Chhattisgarh India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Itolizumab, an anti-CD6 monoclonal antibody, has been recently approved for the off-label indication of cytokine release syndrome in the background of COVID-19, by the Drug Controller General of India. However, this drug has not been included in the National Clinical Management Protocol for COVID-19 yet. The limited-to-no experience of the Indian health workforce with the drug urged us to conduct a situational analysis in the pre-COVID era to analyse the degree of use of the drug and the indications for which it has been employed.

Indexed as

Anti-CD6 monoclonal antibodyApproved indicationsCOVID-19Cytokine stormItolizumabOff-label

Identifiers

PMID33015549
PMCPMC7519855

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.